The full name of the trial is "A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer".

[1] For patients with advanced non-small cell lung carcinoma (NSCLC), maintenance therapy is sometimes used when the initial chemotherapy does not lead to improvement.

[1] The average life of all participants receiving the experimental treatment increased more than 13 months as compared to the control group.

[8] The study was conducted at locations in Australia, Belgium, Finland, France, Germany, Greece, India, Italy, the Netherlands, Poland, Portugal, Romania, Spain, Turkey, and the United Kingdom.

[8] Patients with a history of low-grade (Gleason Grading System score equal to or less than 6) localized prostate cancer are eligible.